



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CHIKV-IN-2

Cat. No.:	HY-132174
CAS No.:	2361289-44-1
Molecular Formula:	C ₂₃ H ₂₆ N ₂ O ₂
Molecular Weight:	362.46
Target:	Dihydroorotate Dehydrogenase; Flavivirus; Dengue virus
Pathway:	Metabolic Enzyme/Protease; Anti-infection
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (275.89 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div><div>Mass</div></div>	1 mg	5 mg	10 mg
		1 mM	2.7589 mL	13.7946 mL	27.5893 mL
		5 mM	0.5518 mL	2.7589 mL	5.5179 mL
		10 mM	0.2759 mL	1.3795 mL	2.7589 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC ₉₀ =270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools ^[1] .
IC ₅₀ & Target	EC90: 270 nM (Chikungunya virus) ^[1] Dihydroorotate Dehydrogenase ^[1]

In Vitro	<p>CHIKV-IN-2 (compound 8q) is a potent pan-alphavirus inhibitor, with EC₉₀s of 0.85-2.5 μM for CHIKV clinical isolates and attenuated vaccine strains^[1].</p> <p>CHIKV-IN-2 is active against alphavirus VEEV (EC₉₀=0.40 μM) as well as flaviviruses such as West Nile Virus (WNV, EC₉₀=0.20 μM) and Dengue Virus Strain-2 (DENV-2, EC₉₀=0.60 μM)^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>																
In Vivo	<p>CHIKV-IN-2 (compound 8q) (80 mg/kg; i.p. twice a day for 3 days) significantly decreases infectious CHIKV dissemination to other tissues of mice^[1].</p> <p>CHIKV-IN-2 (40 mg/kg; p.o., i.p., s.c.) exhibits moderate bioavailability (F=41%, 43%, 4%), terminal elimination half-life (t_{1/2}=9.9, 18.5, 18.6 h) and C_{max} (642, 858, 90 ng/mL) in mice^[1].</p> <p>CHIKV-IN-2 (1 mg/kg; i.v.) exhibits terminal elimination half-life (t_{1/2}= 2.02 h) and AUC (497 h•ng/mL) in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="345 554 1515 825"> <tr> <td>Animal Model:</td><td>Female and male C57BL/6 mice^[1]</td></tr> <tr> <td>Dosage:</td><td>80 mg/kg</td></tr> <tr> <td>Administration:</td><td>I.p. twice a day for 3 days</td></tr> <tr> <td>Result:</td><td>Failed to inhibit virus loads at the site of infection. Decreased virus dissemination to other tissues.</td></tr> </table> <table border="1" data-bbox="345 863 1515 1205"> <tr> <td>Animal Model:</td><td>Male C57BL/6 mice were challenged with CHIKV in the right footpad^[1]</td></tr> <tr> <td>Dosage:</td><td>1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis)</td></tr> <tr> <td>Administration:</td><td>I.v., p.o., i.p., s.c.</td></tr> <tr> <td>Result:</td><td>I.v.: t_{1/2}= 2.02 h; AUC=497 h•ng/mL. P.o.: F=41%; t_{1/2}=9.9 h; C_{max}=642 ng/mL. I.p.: F=43%; t_{1/2}=18.5 h; C_{max}=858 ng/mL. S.c.: F=4%; t_{1/2}=18.6 h; C_{max}=90 ng/mL.</td></tr> </table>	Animal Model:	Female and male C57BL/6 mice ^[1]	Dosage:	80 mg/kg	Administration:	I.p. twice a day for 3 days	Result:	Failed to inhibit virus loads at the site of infection. Decreased virus dissemination to other tissues.	Animal Model:	Male C57BL/6 mice were challenged with CHIKV in the right footpad ^[1]	Dosage:	1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis)	Administration:	I.v., p.o., i.p., s.c.	Result:	I.v.: t _{1/2} = 2.02 h; AUC=497 h•ng/mL. P.o.: F=41%; t _{1/2} =9.9 h; C _{max} =642 ng/mL. I.p.: F=43%; t _{1/2} =18.5 h; C _{max} =858 ng/mL. S.c.: F=4%; t _{1/2} =18.6 h; C _{max} =90 ng/mL.
Animal Model:	Female and male C57BL/6 mice ^[1]																
Dosage:	80 mg/kg																
Administration:	I.p. twice a day for 3 days																
Result:	Failed to inhibit virus loads at the site of infection. Decreased virus dissemination to other tissues.																
Animal Model:	Male C57BL/6 mice were challenged with CHIKV in the right footpad ^[1]																
Dosage:	1 mg/kg for i.v. and 40 mg/kg for p.o., i.p., s.c. (Pharmacokinetic Analysis)																
Administration:	I.v., p.o., i.p., s.c.																
Result:	I.v.: t _{1/2} = 2.02 h; AUC=497 h•ng/mL. P.o.: F=41%; t _{1/2} =9.9 h; C _{max} =642 ng/mL. I.p.: F=43%; t _{1/2} =18.5 h; C _{max} =858 ng/mL. S.c.: F=4%; t _{1/2} =18.6 h; C _{max} =90 ng/mL.																

REFERENCES

[1]. Ahmed SK, et, al. Targeting Chikungunya Virus Replication by Benzoannulene Inhibitors. J Med Chem. 2021 Apr 22;64(8):4762-4786.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA